Concentrations of B cell-activating factor, aquaporin-4 antibody and brain-derived neurotrophic factor in neuromyelitis optica spectrum disorder
Author:
Li Suping1ORCID, Fu Jing2ORCID, Xu Fei1ORCID, Yu Liang1ORCID, Yu Qian2ORCID, Yu Nengwei1ORCID
Affiliation:
1. Department of Neurology , Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital , Chengdu , Sichuan Province , China 2. Department of Medical Rehabilitation , Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital , Chengdu , Sichuan Province , China
Abstract
Abstract
Objectives
To explore the correlations of B cell-activating factor (BAFF), aquaporin-4 antibody (AQP4-Ab) and brain-derived neurotrophic factor (BDNF) with the severity of neuromyelitis optica spectrum disorder (NMOSD).
Methods
Sixty-eight NMOSD patients were selected as an NMOSD group, and 65 patients with non-inflammatory neurological diseases hospitalized in the same period were selected as a control group. The severity of the disease was assessed using the expanded disability status scale (EDSS). Logistic regression analysis was conducted on the influencing factors for the severity of NMOSD. The correlations of BAFF, AQP4-Ab and BDNF with clinical characteristics were studied by Spearman’s analysis.
Results
The patients with EDSS score ≥7 points, number of involved spinal segments ≥5 and recurrence ≥3 times had a lower level of BAFF in the cerebrospinal fluid than the level of those with 4 points ≤ EDSS score <7 points, EDSS score <4 points, number of spinal segments <5 and recurrence <3 times (p<0.05). BAFF concentration was negatively correlated with disease duration, EDSS score, number of involved spinal segments and recurrence status (p<0.05). AQP4-Ab concentration was positively correlated with disease duration, EDSS score, number of involved spinal segments and recurrence status (p<0.05).
Conclusions
The concentrations of BAFF and AQP4-Ab in the cerebrospinal fluid can well predict the progression of NMOSD, correlated with the severity.
Funder
Key Research Project of Science & Technology Department of Sichuan Province
Publisher
Walter de Gruyter GmbH
Subject
Biochemistry (medical),Clinical Biochemistry,Molecular Biology,Biochemistry
Reference28 articles.
1. Levy, M, Fujihara, K, Palace, J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol 2021;20:60–7. https://doi.org/10.1016/s1474-4422(20)30392-6. 2. Winter, A, Chwalisz, B. MRI characteristics of NMO, MOG and MS related optic neuritis. Semin Ophthalmol 2020;35:333–42. https://doi.org/10.1080/08820538.2020.1866027. 3. Hughes, DA, Bourke, S, Jones, A, Bhatt, R, Huda, S, Mutch, K, et al.. Health utilities and costs for neuromyelitis optica spectrum disorder. Orphanet J Rare Dis 2022;17:159. https://doi.org/10.1186/s13023-022-02310-z. 4. Kim, SH, Jang, H, Park, NY, Kim, Y, Kim, SY, Lee, MY, et al.. Discontinuation of immunosuppressive therapy in patients with neuromyelitis optica spectrum disorder with aquaporin-4 antibodies. Neurol Neuroimmunol Neuroinflamm 2021;8:e947. https://doi.org/10.1212/nxi.0000000000000947. 5. Abdel-Mannan, O, Klein, A, Bachar Zipori, A, Ben-Sira, L, Fattal-Valevski, A, Hacohen, Y, et al.. Radiologically isolated aquaporin-4 antibody neuromyelitis optica spectrum disorder. Mult Scler J 2022;28:676–9. https://doi.org/10.1177/13524585221074947.
|
|